Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer
Cancers · 26.06.2025 · 17 (13) · 2153
DOI: 10.3390/cancers17132153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.06.2025. Verfasst von Alexis LeVee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical trials have shown mixed results regarding the benefit of metastasis-directed radiation therapy (MDRT) in oligoprogressive (OP) metastatic breast cancer (MBC), leading to ongoing debate about its role. This study aimed to investigate whether MDRT can prolong the duration of systemic therapy for ≥6 months in patients with OP MBC.
Methods
This retrospective cohort study included patients with MBC who received MDRT for OP disease between December 2017 and March 2023. Patients who received MDRT to the brain were excluded. Medical records were reviewed through July 2024. The primary endpoint was the proportion of patients remaining on the same systemic therapy for ≥6 months post-MDRT.
Results
In total, 52 patients with OP MBC treated with MDRT were included, with 36 (69%) with HR+/HER2- disease, 10 (19%) with HER2+ disease, and 6 (12%) with TNBC. Among the 47 patients with follow-up data available, 28 (60%) remained on their systemic therapy at 6 months, including 65% (22/34) of patients with HR+/HER2- disease, 56% (5/9) with HER2+ disease, and 25% (1/4) with TNBC (p = 0.30). Among the 38 patients with a follow-up time of at least 1 year post-MDRT, 47% (18/38) remained on the same systemic therapy. The median time to next systemic therapy and median PFS were 6.9 months (95% CI, 5.7–14.7) and 6.2 months (95% CI, 4.1–9.7), respectively.
Conclusions
Over half of patients with OP MBC remained on the same systemic therapy for at least 6 months following MDRT, which suggests that MDRT may help prolong systemic therapy duration for select patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
ORCID-Profile: Alexis LeVee, Stephanie Yoon, Joanne Mortimer
Zitieren
APA
LeVee, A., Young, H., Yoon, S., Glaser, S., Wu, S., Mortimer, J., & Bazan, J. G. (2025). Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer. Cancers, 17(13), 2153. https://doi.org/10.3390/cancers17132153
Vancouver
LeVee A, Young H, Yoon S, Glaser S, Wu S, Mortimer J, et al. Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer. Cancers. 2025;17(13):2153. doi:10.3390/cancers17132153
BibTeX
@article{LeVee2025,
author = {LeVee, Alexis and Young, Hannah and Yoon, Stephanie and Glaser, Scott and Wu, Shengyang and Mortimer, Joanne and Bazan, Jose G},
title = {Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {13},
pages = {2153},
doi = {10.3390/cancers17132153}
}
EUVIMED